Skip to content
LATEST
Health

FDA Approves First Functional Cure for Chronic Hepatitis B

The FDA has approved bepirovirsen as the first functional cure for chronic hepatitis B, offering a finite treatment course that maintains viral suppression…

FDA Approves First Functional Cure for Chronic Hepatitis B

The U.S. Food and Drug Administration (FDA) has approved bepirovirsen, marketed as Hibsago, for the treatment of chronic hepatitis B (CHB). This approval marks the introduction of the first therapy classified as a "functional cure," capable of suppressing the virus to undetectable levels in the blood even after the cessation of treatment.

Clinical data from two phase 3 trials demonstrated that a six-month course of the drug achieved a functional cure in 19 percent of participants, defined as maintaining undetectable viral levels for at least 24 weeks post-treatment. In contrast, the placebo group showed no such response. The drug is administered via weekly injections and may be used in conjunction with existing antiviral medications, which can be discontinued if the patient achieves the functional cure threshold.

Despite the clinical efficacy, the drug carries risks of serious side effects, specifically liver inflammation, necessitating regular monitoring through blood tests. Furthermore, the long-term durability of the cure beyond the 72-week study period remains unverified, and the treatment is most effective in patients who present with lower baseline levels of specific viral proteins.

This development shifts the standard of care from indefinite viral suppression to a finite treatment duration for a subset of the patient population. The manufacturer intends to expand global availability, while researchers continue to investigate combination therapies to improve the overall response rate. The approval addresses a significant public health burden, as CHB is a primary driver of global liver cancer cases.

More stories

Latest news